#China #Shanghai #Moyom Biotechnology #Aphranel #CaHA Filler

Aphranel® MagiCCrystal CaHA Filler Achieves EU MDR Certification

Moyom Biotechnology has announced a significant milestone with its product Aphranel® MagiCCrystal CaHA Filler, which officially received certification under the European Union Medical Device Regulation (EU MDR) on May 18, 2026. This certification is a testament to the product's alignment with the rigorous standards set forth by the EU, signifying compliance in areas such as manufacturing quality, clinical evaluation, and post-market surveillance.

As one of the first regenerative Calcium Hydroxylapatite (CaHA) injectable fillers from the Asia-Pacific region to obtain this recognition, Aphranel® stands out not only for its innovative formulation but for its long-term development strategy that prioritizes safety and efficacy over expedience. This announcement is particularly important as the European market increasingly enforces stricter compliance requirements since the implementation of the EU MDR in May 2021, which replaced the previous Medical Device Directive (MDD).

The certification process, done through the rigorous MDR Class III pathway, spanned approximately 2 years and 7 months. This pathway is specifically tailored for high-risk medical devices without equivalence routes or exemptions, highlighting the complexities and challenges Moyom faced during the compliance journey. The company's proactive approach, including collaborations with BSI, a noted UK-based Notified Body, played a critical role in navigating the certification landscape.

The Aphranel® MagiCCrystal CaHA Filler is not merely a plastic surgery product but reflects a broader vision in regenerative aesthetics. It includes a special blend of 30% CaHA microspheres and 70% CMC gel, designed to provide immediate support while also stimulating natural collagen production in the body. The goal of this design is not just to achieve aesthetic results but to promote long-lasting structural improvements.

The technology utilized, including patented structures such as ACD-MT® microspheres and PCD-ETT® gel, emphasizes the product's advanced biological compatibility. The microspheres, characterized by a unique raspberry-shaped porous structure, are designed for optimal tissue integration and sustained collagen generation. Notably, these microspheres are free of residual chemical agents, which allows for a natural degradation process where calcium ions are metabolized in the body, ensuring long-term compatibility and reduced risk of adverse reactions.

Positioned at a higher-end price point, the Aphranel® filler retails at RMB 12,800 for a 0.5 mL syringe, reflecting its high-quality formulation and market positioning. Within the competitive landscape of China's premium medical aesthetics sector, Moyom Biotechnology strives to redefine standard practices and consumer expectations.

Aphranel has effectively communicated its philosophy through the concept of "The Poetics of Time," which captures its commitment to gradual, natural beautification that emphasizes longevity and gradual improvement over quick fixes. This ethos was also showcased during the company's presence at the notable IMCAS Paris 2026 congress, expanding its academic and professional outreach on the global stage.

In conclusion, the achievement of EU MDR certification for Aphranel® MagiCCrystal CaHA Filler not only marks a pivotal moment for Moyom Biotechnology but also represents a leap forward in the global regenerative aesthetics field. As this industry continues to evolve, innovations such as this filler will likely shape the future of aesthetic treatments, prioritizing patient safety and product efficacy in equal measure. It confirms Moyom's belief that a global leader in regenerative aesthetics can indeed emerge from China, positioning itself as a strong contender in a field traditionally dominated by a handful of international players.